Rincon Bio performs OCI-AML-3 xenograft models to test efficacy of preclinical therapies. Please see below for additional information or to request a quote.
OCI-AML-3 was derived from a 57 year old man with acute myeloid leukemia in 1987.
NPM1 mutation and DNMT3A R882C mutation
Used in xenografts to test the efficacy of novel cancer therapeutics. Tumors develop after being injected into the flank of immunocompromised mice.
Rincon Bio Growth Curves
Cell Line: OCI-AML3
Mouse Strain: NOD.CB17-Prkdc*scidNCrHsd females (Envigo)
Animals per Group: 10
Positive Control: None
From implant to stratification: 14 days
Cells Implanted per Animal: 10 million
WHY WORK WITH
When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices
Most efficacy studies can be initiated within two business days.
We love our clients! We are flexible and easy to work with. And we take a personal interest in our clients' studies.